A metoprolol sustained-release drug composition and a preparation method therefor. The composition comprises: a. a blank sucrose pill core

Provided in the present invention is a joint product containing synephrine and topiramate, where the synephrine or a salt thereof is administered in the form of an immediate-release preparation, preferably an immediate-release pellet, with a daily dosage between 2 mg and 25 mg, preferably between 5 mg and 20 mg, and where the topiramate is administered in the form of a sustained-release or controlled-release preparation, preferably a sustained-release pellet, with a daily dosage between 20 mg an...

Provided in the present invention is a joint product comprising a phentermine immediate-release pellet and a topiramate sustained-release pellet. The topiramate pellet comprises: a. a blank pellet core

A topiramate sustained-release pharmaceutical composition comprising no binders. The topiramate sustained-release pharmaceutical composition is a sustained-release pellet, comprising a blank pill core, a medicament layer, and a sustained-release coating layer.

The invention discloses novel piperazine derivatives represented by formula I having activity for modulating dopamine D3 receptor, their stereoisomers, pharmaceutical salts, solvates, and the pharmaceutical compositions containing such compounds, their preparation and the use of such compounds for preventing or treating the diseases correlated with central nervous system disorder, such as Parkinson's disease, schizophrenia, drug addiction and relapse and the like, as well as the use of such comp...